6890-38-6

Basic information

• Product Name: 2,5-Dimethylpyrazine 1,4-dioxide
• Synonyms: 2,5-Dimethylpyrazine 1,4-dioxide
• CAS NO: 6890-38-6
• Molecular Formula: C6H11N2O2+
• Molecular Weight: 140.14
• Mol File: 6890-38-6.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2,5-Dimethylpyrazine 1,4-dioxide(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-Dimethylpyrazine 1,4-dioxide(6890-38-6)
• EPA Substance Registry System: 2,5-Dimethylpyrazine 1,4-dioxide(6890-38-6)

Safety Data

• Hazardous Substances Data: 6890-38-6(Hazardous Substances Data)

Usage

Appearance

White crystalline solid

Melting point

135-138°C

Usage

Flavoring agent in the food industry

Aroma

Nutty and roasted

Common applications

Added to coffee, chocolate, and baked goods

Other uses

Production of fragrances

Safety precautions

Potentially harmful if ingested or inhaled in large quantities, should be handled and stored with care.

InChI:InChI=1/C6H8N2O2/c1-5-3-8(10)6(2)4-7(5)9/h3-4H,1-2H3

Upstream product

• 123-32-0 2,5-dimethyl-pyrazine 

Downstream Products

• 6277-35-6 N-methylpyrazinium iodide 
• 3803-16-5 N-methyl-2,5-dimethylpyrazinium iodide 
• 21899-24-1 2,5-(E,E)-distyrylpyrazine 
• 73290-46-7 2,5-di-trans-styryl-pyrazine-1,4-dioxide 

Relevant articles and documents

-

-

Pyrazine-fused isoindigo: A new building block for polymer solar cells with high open circuit voltage

Pyrazine-fused isoindigo (PzIIG) was designed and synthesized as a novel electron acceptor to construct two D-A conjugated polymers, PzIIG-BDT2TC8 and PzIIG-BTT2TC10. Both the polymers were successfully applied in polymer solar cells, and the PzIIG-BDT2TC8 based solar cell device exhibited a PCE of 5.26% with a high Voc over 1.0 V.

BIS-AMINES, COMPOSITIONS, AND USES RELATED TO CXCR4 INHIBITION

This disclosure relates bis-amine compounds disclosed herein and uses related to CXCR4 inhibition. In certain embodiments, the compounds have formula (I), salts, derivatives, and prodrugs thereof wherein, A is a bridging aryl or heterocyclyl and R1 and R2 are further disclosed herein. In certain embodiments, the disclosure contemplates pharmaceutical compositions comprising compounds disclosed herein. In certain embodiments, the disclosure relates to methods of treating or preventing CXCR4 related diseases or conditions by administering an effective amount of a compound disclosed herein to a subject in need thereof.